
Robert H Wichers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5568917/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2018, 32, 3-29.	4.0	196
2	Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology, 2019, 44, 1398-1405.	5.4	95
3	The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). Journal of Psychopharmacology, 2019, 33, 1141-1148.	4.0	51
4	Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy. Translational Psychiatry, 2019, 9, 313.	4.8	36
5	Modulation of brain activation during executive functioning in autism with citalopram. Translational Psychiatry, 2019, 9, 286.	4.8	14
6	Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin. Molecular Autism, 2021, 12, 49.	4.9	13
7	Serotonin differentially modulates the temporal dynamics of the limbic response to facial emotions in male adults with and without autism spectrum disorder (ASD): a randomised placebo-controlled single-dose crossover trial. Neuropsychopharmacology, 2020, 45, 2248-2256.	5.4	7
8	Modulation of atypical brain activation during executive functioning in autism: a pharmacological MRI study of tianeptine. Molecular Autism, 2021, 12, 14.	4.9	6
9	Differences in social brain function in autism spectrum disorder are linked to the serotonin transporter: A randomised placebo-controlled single-dose crossover trial. Journal of Psychopharmacology, 2022, 36, 723-731	4.0	6